Vitrafy Life Sciences Limited (ASX:VFY)
Australia
· Delayed Price · Currency is AUD
1.478
-0.032 (-2.15%)
At close: Jun 10, 2025, 4:00 PM AEST
Vitrafy Life Sciences Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| Net Income | -36.06 | -10.43 | -7.81 | -7.66 |
| Depreciation & Amortization | 0.17 | 0.21 | 0.26 | 0.19 |
| Other Amortization | 2.03 | 2.03 | 0.81 | - |
| Stock-Based Compensation | 0.19 | 0.19 | 0.36 | 0.11 |
| Other Operating Activities | 27.74 | 1.78 | 0.65 | 3.03 |
| Change in Accounts Receivable | -0.05 | -0.05 | -0.02 | -0.02 |
| Change in Accounts Payable | -0.23 | -0.23 | 0.31 | -0.11 |
| Change in Other Net Operating Assets | -0.3 | -0.3 | 0.49 | -1.42 |
| Operating Cash Flow | -6.5 | -6.79 | -4.96 | -5.87 |
| Capital Expenditures | -0.01 | -0.01 | -0.09 | -0.49 |
| Investing Cash Flow | -20.01 | -0.01 | -0.09 | -0.49 |
| Short-Term Debt Issued | - | 12.55 | 6.31 | - |
| Total Debt Issued | 5.86 | 12.55 | 6.31 | - |
| Short-Term Debt Repaid | - | -0.55 | -0.4 | - |
| Long-Term Debt Repaid | - | -0.13 | -0.1 | -0.06 |
| Total Debt Repaid | -0.23 | -0.68 | -0.5 | -0.06 |
| Net Debt Issued (Repaid) | 5.64 | 11.87 | 5.82 | -0.06 |
| Issuance of Common Stock | 35.59 | 0.27 | 0.09 | - |
| Other Financing Activities | -3.75 | -0.64 | -0.1 | - |
| Financing Cash Flow | 37.47 | 11.5 | 5.8 | -0.06 |
| Net Cash Flow | 10.96 | 4.69 | 0.76 | -6.42 |
| Free Cash Flow | -6.51 | -6.8 | -5.05 | -6.36 |
| Free Cash Flow Margin | - | -18308.88% | -245.44% | -348.32% |
| Free Cash Flow Per Share | -0.45 | -2.22 | -1.71 | -2.17 |
| Levered Free Cash Flow | - | -10.59 | 0.73 | - |
| Unlevered Free Cash Flow | - | -4.07 | 3.86 | - |
| Change in Net Working Capital | - | -0.2 | -6.98 | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.